Pfizer (PFE)
(Delayed Data from NYSE)
$28.86 USD
+0.41 (1.44%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $28.97 +0.11 (0.38%) 7:04 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.86 USD
+0.41 (1.44%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $28.97 +0.11 (0.38%) 7:04 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
5 Big ETF Stories of 2020 Worth Watching in 2021
by Sweta Killa
We discuss some of the events that dominated the headlines in 2020 and are worth watching in 2021.
Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
AstraZeneca (AZN) COVID-19 Vaccine Gets Authorization in UK
by Zacks Equity Research
AstraZeneca's (AZN) vaccine for coronavirus receives emergency use approval in the United Kingdom, the first for it anywhere in the world.
Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study update from Novavax (NVAX) and antibody cocktail treatment update from Regeneron (REGN).
4 Best Performing Sector ETFs of December
by Sweta Killa
Despite the surge in coronavirus cases, December has been kind for the U.S. stock market with the major indices enjoying a historic rally.
Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results
by Zacks Equity Research
Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.
5 Factors Indicating That Oil is Poised for a Run-Up in 2021
by Nilanjan Choudhury
As a proof of the improving energy environment, refining biggies like Marathon Petroleum (MPC) and Phillips 66 (PSX) experienced sequential increase in utilization during the third quarter.
Wall Street Stories That Hit Headlines in 2020
by Sweta Killa
With super-easy policies and vaccination, small-cap stocks like Liquidity Services (LQDT) and cyclical stocks like Nexstar Media (NXST), Deere & Company (DE) and BHP Billiton (BBL) are expected to benefit the most.
Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug
by Zacks Equity Research
Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $37.05, marking a +0.62% move from the previous day.
Bristol Myers' (BMY) Application for UC Drug Validated by EMA
by Zacks Equity Research
Bristol Myers' (BMY) MAA for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis gets validated by EMA.
Myovant (MYOV) Up on Collaboration With Pfizer for Relugolix
by Zacks Equity Research
Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.
Novavax (NVAX) Initiates Phase III Study on COVID-19 Vaccine
by Zacks Equity Research
Novavax (NVAX) initiates phase III study on its coronavirus vaccine, NVX-CoV2373, in the United States and Mexico.
AstraZeneca's (AZN) Lynparza Approved in Japan for 3 Cancers
by Zacks Equity Research
AstraZeneca (AZN) and partner Merck's Lynparza is approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.
Pfizer (PFE) Lorbrena First-Line sNDA Gets FDA Priority Review
by Zacks Equity Research
Pfizer's (PFE) label expansion application for Lorbrena as first-line treatment for metastatic lung cancer gets priority review from the FDA.
Company News for Dec 29, 2020
by Zacks Equity Research
Companies In The News Are: TSLA, LMT, MYOV, PFE, DASH
4 Transportation Stocks Likely to Keep Flying High in 2021
by Maharathi Basu
Robust advancement in e-commerce and an uptick in freight conditions make transportation stocks attractive investment bets. Evidently, the likes of UPS, Knight-Swift (KNX), Atlas Air (AAWW) and ArcBest (ARCB) should grace one's portfolio.
5 Sector ETFs That Beat the Market in 2020
by Sweta Killa
With historic twists and turns, 2020 has turned out to be a banner year.
3 Restaurant Stocks to Gain Big With the Vaccine Rollout
by Zacks Equity Research
Restaurant industry is likely to benefit from the vaccine rollout. Following the vaccine rollout, dine-in option should become safe and traffic is likely to increase.
5 Stocks That Could Directly Gain From Pfizer's Vaccine Success
by Zacks Equity Research
As vaccine rollout picks up in the United States, companies directly involved in the distribution process stand to benefit, making it wise to keep an eye on names like FedEx (FDX) and Linde (LIN)
The Zacks Analyst Blog Highlights: Apple, JPMorgan, Union Pacific, Pfizer and Lockheed Martin
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, JPMorgan, Union Pacific, Pfizer and Lockheed Martin
Allogene's (ALLO) AlloCAR T Therapy ALLO-715 IND Gets FDA Nod
by Zacks Equity Research
The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.
Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to U.S.
by Zacks Equity Research
Pfizer (PFE)/BioNTech(BNTX) won a deal for 100 million more doses of its COVID-19 vaccine in the United States.
Evergreen Tree of ETFs to Lighten Your Christmas
by Sweta Killa
The Christmas tree of top-ranked ETFs to brighten 2021 is now ready for investors. May it spread cheer!
Stock Market News for Dec 24, 2020
by Zacks Equity Research
Benchmarks closed mixed on Wednesday after investors¿¿¿ sentiment were overshadowed by President Trump¿¿¿s opposition on fresh stimulus packages passed by the Congress.